Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.

NCT07056205 | Enrolling By Invitation DMC

• 1 other identifier: Soh-Med--25-5-1MS
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion

Conditions

Breast Cancer

Keywords

ER,PR,HER2/neu,breast cancer

Outcome Measures

Primary Outcomes (1)

• Comparison between initial and recurrent breast cancer in immunohistochemical expression of ER,PR and HER2/neu

  6 months

Secondary Outcomes (1)

• Correlate the results of immunohistochemical expression of ER,PRand HER2/neu with the patients age ,sex,nodal status and lymphovascular invasion

  6 months

Study Arms (1)

archived histological slides and immune-stained slides of 100 patient with breast cancer

Eligibility Criteria

• Gender Eligibility Details: \- Inclusion criteria: Patients with excised breast cancer then experienced recurrence at same site. Patients with evaluated ER, PR and HER2/neu for both initial and recurrent tumors. \- Exclusion criteria: Cases with insufficient clinical of pathological data. Deficient ER, PR and HER2/neu status in either initial or recurrent tumor
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

archived histological slides and immune-stained slides of100 patient with initial and recurrent mammary carcinoma will be obtained from Pathology Laboratory at Sohag Oncology Center.

You may qualify if:

• Patients with excised breast cancer then experienced recurrence at same site. Patients with evaluated ER, PR and HER2/neu for both initial and recurrent tumors.

You may not qualify if:

• Cases with insufficient clinical of pathological data. Deficient ER, PR and HER2/neu status in either initial or recurrent tumor

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Faculty of medicine

Sohag, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Archived histological slides and immune-stained slides of 100 patient with initial and recurrent mammary carcinoma will be obtained from Pathology Laboratory at Sohag Oncology Center.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Comparative expression of ER, PR and HER2/neu in initial and recurrent breast cancer.

Study Record Dates

• First Submitted: June 29, 2025
• First Posted: July 9, 2025
• Study Start: January 1, 2021
• Primary Completion: October 1, 2025
• Study Completion: December 1, 2025
• Last Updated: July 9, 2025

Record last verified: 2025-05

Locations

EG (1)